A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Conditions
Multiple Myeloma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Saad Usmani)Alberta Health Services AHS - Foothills Medical Centre FMC, Calgary, Alberta, Canada
University of Alberta - Cross Cancer Institute, Edmonton, Alberta, Canada
University Health Network UHN - Princess Margaret Hospital PMH, Toronto, Ontario, Canada
Oslo University Hospital, Oslo, Outside US and Canada, Norway
ICO - Hospital Germans Trias i Pujol, Barcelona, Spain
Hospital Universitario 12 de Octubre, Madrid, Spain
Hospital Universitario Marques de Valdecilla, Santander, Spain
The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
Local Institution - 0001, Leicester, Leicestershire, United Kingdom
Local Institution - 0014, Liverpool, Merseyside, United Kingdom
Churchill Hospital, Oxford, Oxfordshire, United Kingdom
NIHR UCLH Clinical Research Facility, London, United Kingdom
Study leads
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb